SCHEMBL14769164

SCHEMBL14769164

Cc1ccc(CNC(=O)c2cnc(S(C)(=O)=O)nc2Cc2cccc(NC(=O)OC(C)(C)C)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.41
RPS6KB1 P23443 2/20 0.41
TP53 P04637 4/20 0.40
LMNA P02545 1/20 0.40
NAMPT P43490 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14772001 0.92 BTK (0.44) AURKARPS6KB1TP53LMNASIRT2
SCHEMBL14769185 0.88 RXFP1 (0.51) AURKARPS6KB1TP53LMNANAMPT
SCHEMBL14769222 0.87 MAPT (0.42) AURKARPS6KB1TP53LMNANAMPT
SCHEMBL13498140 0.85 NPC1 (0.42) AURKARPS6KB1TP53LMNANAMPT
SCHEMBL14769227 0.82 CNR2 (0.57) LMNARXFP1POLBMAPTALDH1A1
SCHEMBL14772002 0.80 POLB (0.53) AURKARPS6KB1LMNARXFP1SIRT2
SCHEMBL21110444 0.78 BTK (0.58) TP53LMNANPC1RAB9APOLB
SCHEMBL12518624 0.78 MEN1 (0.47) TP53LMNANPC1RAB9APOLB
SCHEMBL14772003 0.77 CNR2 (0.59) POLBMAPTALDH1A1MEN1KMT2A
SCHEMBL14769208 0.75 BTK (0.49) AURKARPS6KB1NAMPTHPGDBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710222-B2 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE AVILOMICS RESEARCH, INC. (US) 2014-04-29 US disclosed
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065899-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 AURKA 1849/4885RPS6KB1 3635/4885TP53 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.